Evidence map›Paper›PMID 38118011›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Collecting Multi-country Retrospective Antimicrobial Consumption and Use Data: Challenges and Experience.

Kristi Prifti, Kyu-Young Kevin Chi, Emmanuel Eraly, Hea Sun Joh, Mohammad Julhas Sujan, Nimesh Poudyal, Florian Marks, Marianne Holm

Erratum issuedAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. CAPTURA Regional Workshop Proceedings (28-30 June 2022, Virtual).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Kristi PriftiInternational Vaccine Institute, Seoul, Republic of Korea.
Kyu-Young Kevin ChiInternational Vaccine Institute, Seoul, Republic of Korea.
Emmanuel EralyInternational Vaccine Institute, Seoul, Republic of Korea.
Hea Sun JohInternational Vaccine Institute, Seoul, Republic of Korea.
Mohammad Julhas SujanInternational Vaccine Institute, Seoul, Republic of Korea.
Nimesh PoudyalInternational Vaccine Institute, Seoul, Republic of Korea.
Florian MarksInternational Vaccine Institute, Seoul, Republic of Korea.
Marianne HolmInternational Vaccine Institute, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excessive or inappropriate antimicrobial use contributes to antimicrobial resistance, emphasizing the need to monitor and document the types and quantities of antibiotics used. Thus, data on antimicrobial consumption (AMC) and antimicrobial usage (AMU) are key in informing and promoting judicious use. Our study, conducted during 2019-2023, as part of the CAPTURA project, aimed to understand the state of data availability and quality for AMC and AMU monitoring in Asia. In this article, we describe the challenges and opportunities faced and provide examples of AMU and AMC analysis. World Health Organization (WHO) and country-tailored methodologies and tools were applied to collect retrospective data from 2016 to 2019 in Bangladesh, Bhutan, Laos, Nepal, Pakistan, Papua New Guinea, Sri Lanka, and Timor-Leste. The primary indicator for national AMC was total level of consumption, expressed as total defined daily doses (DDD) per 1000 inhabitants per day for the year or period of data collected. For facility AMC and AMU, the primary indicator was total DDD per admissions per day for the year or period of data collected. Although many countries faced infrastructural challenges in data collection and storage, we managed to collect and analyze AMC data from 6 countries and AMU data from 5. The primary indicators, and additional findings, were visualized to facilitate dissemination and promote the development of action plans. Looking ahead, it is crucial that future initiatives empower each country to establish surveillance infrastructures tailored to their unique contexts, ensuring sustainable progress in the fight against antimicrobial resistance.

Indexed as

Anti-Infective AgentsAnti-Bacterial AgentsHumansPakistanRetrospective StudiesWorld Health OrganizationAnti-Bacterial AgentsAnti-Infective AgentsAMC indicatorsAMUantimicrobial usageconsumptiondata collectionmulti-country

Identifiers

PMID38118011
PMCPMC10732554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.